logo

Cassava Sciences Inc (SAVA)



Trade SAVA now with
  Date
  Headline
8/25/2021 7:35:56 AM Cassava Sciences Responds To Allegations; Stock Down
8/24/2021 8:36:38 AM Cassava Sciences Agrees With FDA On Special Protocol Assessments For Simufilam Phase 3 Studies For Alzheimer’s Disease
6/14/2021 8:36:01 AM Cassava Sciences Names Richard Barry To Board, Effective June 11
2/22/2021 8:42:27 AM Cassava Sciences Announces Completion Of An End-of-Phase 2 Meeting With FDA For Simufilam
11/9/2020 8:26:37 AM Cassava Sciences Q3 Net Loss $1.4 Mln Or $0.06/Shr Vs Loss $0.7 Mln Or $0.04/Shr Last Year